Bimekizumab Continuous Maintenance of Eesponse at Every Visit Through Two Years in Patients with Moderate to Severe Plaque Psoriasis: Post-hoc Results from Five Phase 3/3b Trials. J of Skin. 2024;8(1):s303. doi:10.25251/skin.8.supp.303